Pegvisomant (Somavert)
Overview
Pegvisomant is a PEGylated growth hormone receptor antagonist engineered from human growth hormone with nine amino acid substitutions that confer antagonist properties. The molecule binds to growth hormone receptors but does not activate downstream signaling, effectively blocking the action of endogenous growth hormone. It is used exclusively for the treatment of acromegaly in patients with inadequate response to surgery or other medical therapies.
Key Research Findings
FDA approval was granted in 2003 based on pivotal trials demonstrating normalization of IGF-1 levels in the majority of acromegaly patients, with results published in the Journal of Clinical Endocrinology and Metabolism in 2000. Long-term extension studies have confirmed sustained biochemical control and symptom improvement. Pegvisomant is recommended in clinical guidelines for refractory acromegaly.
Subcutaneous injection
FDA Approved
Interested in Pegvisomant (Somavert)?
Find a verified provider experienced with Pegvisomant (Somavert) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Pegvisomant (Somavert) ProviderRelated Peptides
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days. CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.
Ipamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH release. Unlike other GH secretagogues, ipamorelin does not significantly affect ACTH, cortisol, or prolactin levels, making it one of the most specific GH-releasing peptides. It works synergistically with GHRH analogs like CJC-1295.
Sermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates the pituitary to produce and release growth hormone through the natural GHRH receptor pathway, preserving the hypothalamic-pituitary feedback axis. It maintains physiological pulsatile GH secretion patterns.
Tesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways. It is the only FDA-approved treatment for HIV-associated lipodystrophy.